Relmada Therapeutics ( (RLMD) ) has shared an update.

Relmada Therapeutics , Inc. (NASDAQ:RLMD), a pharmaceutical company currently valued at $13.5 million, announced the appointment of Paul Kelly as Chief Operating Officer (COO) effective January 1 ...

Relmada Therapeutics , Inc. (NASDAQ:RLMD), a pharmaceutical company currently valued at $13.5 million, announced the appointment of Paul Kelly as Chief Operating Officer (COO) effective January 1, ...

On Tuesday, Jefferies, a global investment banking firm, upgraded Relmada Therapeutics Inc (NASDAQ:RLMD) stock from Hold to Buy, significantly raising the price target to ...